Article
Focal Adhesion Kinase (FAK) tyrosine 397E mutation restores the vascular leakage defect in endothelium-specific FAK-kinase dead mice.
The Journal of pathology - 1 Jul 2017
Alexopoulou Annika N, Lees Delphine M, Bodrug Natalia, Lechertier Tanguy, Fernandez Isabelle, D'Amico Gabriela, Dukinfield Matthew, Batista Silvia, Tavora Bernardo, Serrels Bryan, Hodivala-Dilke Kairbaan
Abstract excerpt
Focal adhesion kinase (FAK) inhibitors have been developed as potential anticancer agents and are undergoing clinical trials. In vitro activation of the FAK kinase domain triggers autophosphorylation of Y397, Src activation, and subsequent phosphorylation of other FAK tyrosine residues. However, how FAK Y397 mutations affect FAK kinase-dead (KD) phenotypes in tumour angiogenesis in vivo is unknown. We developed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.